Peter Whitehouse, MD, PhD, of The Taos Institute, Chagrin Falls, OH, discusses the recent results of clinical trials investigating the safety and efficacy of aducanumab in Alzheimer’s disease (AD). Aducanumab was fast-tracked by the Food and Drug Administration (FDA) for approval based on biomarker data. The results of these trials suggest that aducanumab is not clinically effective in AD and is associated with intolerable side effects. Aducanumab administration also requires complex testing and visits to infusion centers. Taken together, these results suggest that aducanumab is not a viable treatment for AD. Extra consideration should be taken in the future when fast-tracking treatments for approval to prevent similar cases from occurring. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy) meeting.